4-甲基-苯并呋喃-2-羧酸 | 5670-24-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 4-甲基-苯并呋喃-2-羧酸
• 英文名称: 4-Methyl-benzofuran-2-carbonsaeure
• 英文别名: 4-Methylbenzofuran-2-carboxylic acid；4-methyl-1-benzofuran-2-carboxylic acid
• CAS: 5670-24-6
• 化学式: C₁₀H₈O₃
• 分子量: 176.172
• InChiKey: SNKGYZVEYQQMFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-甲基-苯并呋喃-2-羧酸 在 sodium amalgam 作用下， 以 sodium hydroxide 为溶剂， 反应 2.5h， 生成 4-甲基-2,3-二氢苯并呋喃-2-羧酸
  参考文献：
  名称：

  .alpha.-Adrenoceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on .alpha.-adrenoreceptor activity

  摘要：

  Modification of the 1,4-benzodioxan ring present in RX 781094 has not previously been considered. This paper describes a number of analogues of this ring system, including compounds in which one of the oxygen atoms has been replaced by a methylene group and also those in which the ring size has been changed to give, for example, furan and thiophene derivatives. The dihydrobenzofuranylimidazoline compound 7 is the only analogue possessing presynaptic antagonist potency potency and selectivity comparable to that of 1. In view of this result, a number of derivatives was prepared to determine the structure-activity relationships within this series. Many derivatives, as well as the parent compound 7, were found to possess presynaptic alpha 2-adrenoreceptor antagonist and postsynaptic alpha 1-adrenoreceptor partial agonist properties. Two of the selective presynaptic antagonists, 13 and 14 possess greater potency and selectivity than that possessed by 1. The 5-chloro derivative 25 is twice as potent as after oral administration but only about half as potent when given intravenously.

  DOI：

  10.1021/jm00371a003
• 作为产物：
  描述：

  2-羟基-6-甲基苯甲醛 、 溴代丙二酸二乙酯 在 potassium carbonate 、 丁酮 作用下， 生成 4-甲基-苯并呋喃-2-羧酸
  参考文献：
  名称：

  Pappalardo; Duro, Bollettino Scientifico della Facolta di Chimica Industriale di Bologna, 1952, vol. 10, p. 168

  摘要：

  DOI：

文献信息

• 硼酸类化合物及其制备方法和用途
  申请人：复旦大学

  公开号：CN107151255A

  公开（公告）日：2017-09-12

  本发明涉及药物化学和药物治疗学领域。具体涉及新的硼酸类化合物及其制备方法和用途，尤其涉及新的取代五元杂环硼酸类及取代苯并五元杂环硼酸类化合物及其制备方法，本发明制得的如下式结构的取代五元杂环硼酸类及取代苯并五元杂环硼酸类化合物经生物活性筛选试验，结果表明，所述的化合物具有抑制蛋白酶体的功能，可进一步用于制备治疗与蛋白酶体相关疾病的药物。
• Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
  申请人：Bora Martin Keenan

  公开号：US20050004167A1

  公开（公告）日：2005-01-06

  The invention relates to BCAT inhibitor compounds of formula (I) and use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

  本发明涉及公式（I）的BCAT抑制剂化合物及其用于治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失，以及治疗神经退行性疾病，包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病和唐氏综合症，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑、精神病、惊厥、氨基糖苷类抗生素引起的听力损失、偏头痛、慢性疼痛、神经病性疼痛、帕金森病、糖尿病视网膜病变、青光眼、巨细胞病毒性视网膜炎、尿失禁、阿片类耐受或戒断，以及诱导麻醉和增强认知功能。
• BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS
  申请人：Roche Didier

  公开号：US20110105475A1

  公开（公告）日：2011-05-05

  The present invention relates to compounds of formula (I) wherein the substituents are as defined in the claims, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention and/or amelioration of one or more symptoms of disease or disorders related to the activity of FXR. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).

  本发明涉及公式（I）化合物，其中取代基如权利要求中所定义，包括其药物组合物以及用于治疗和/或预防和/或改善与FXR活性相关的一种或多种疾病或障碍的症状的用途。本发明还涉及中间体以及制备公式（I）化合物的方法。
• Pappalardo; Duro, Bollettino Scientifico della Facolta di Chimica Industriale di Bologna, 1952, vol. 10, p. 168
  作者：Pappalardo、Duro

  DOI：——

  日期：——
• Aminoalkyl benzofuran derivatives, their production and compositions containing them
  申请人：Merck & Co., Inc.

  公开号：EP0029311B1

  公开（公告）日：1985-01-23